Published in Expert Opin Pharmacother on December 26, 2013
Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400. Clin Cancer Res (2015) 1.35
SCF ubiquitin ligase-targeted therapies. Nat Rev Drug Discov (2014) 1.25
CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer. Oncotarget (2014) 1.10
Targeting cancer stem cell propagation with palbociclib, a CDK4/6 inhibitor: Telomerase drives tumor cell heterogeneity. Oncotarget (2017) 0.92
Invasive Bladder Cancer: Genomic Insights and Therapeutic Promise. Clin Cancer Res (2015) 0.88
Update on adjuvant chemotherapy for early breast cancer. Breast Cancer (Auckl) (2014) 0.86
Induction of Therapeutic Senescence in Vemurafenib-Resistant Melanoma by Extended Inhibition of CDK4/6. Cancer Res (2016) 0.85
Breast Cancer Update 2014 - Focus on the Patient and the Tumour. Geburtshilfe Frauenheilkd (2015) 0.85
Cyclin-dependent kinase pathway aberrations in diverse malignancies: clinical and molecular characteristics. Cell Cycle (2015) 0.83
Efficacy of CDK4 inhibition against sarcomas depends on their levels of CDK4 and p16ink4 mRNA. Oncotarget (2015) 0.82
New targeted therapies for breast cancer: A focus on tumor microenvironmental signals and chemoresistant breast cancers. World J Clin Cases (2014) 0.82
Pharmacological cyclin dependent kinase inhibitors: Implications for colorectal cancer. World J Gastroenterol (2016) 0.80
Cancer biomarker discovery is improved by accounting for variability in general levels of drug sensitivity in pre-clinical models. Genome Biol (2016) 0.79
Genomic portfolio of Merkel cell carcinoma as determined by comprehensive genomic profiling: implications for targeted therapeutics. Oncotarget (2016) 0.78
Treatment strategy for metastatic breast cancer with estrogen receptor-positive tumor. Int J Clin Oncol (2015) 0.77
Mitotic Checkpoint Kinase Mps1 Has a Role in Normal Physiology which Impacts Clinical Utility. PLoS One (2015) 0.77
Genomic landscape of salivary gland tumors. Oncotarget (2015) 0.76
Combined PI3K and CDK2 inhibition induces cell death and enhances in vivo antitumour activity in colorectal cancer. Br J Cancer (2016) 0.76
Cotargeting of CYP-19 (aromatase) and emerging, pivotal signalling pathways in metastatic breast cancer. Br J Cancer (2016) 0.75
Discovering novel pharmacogenomic biomarkers by imputing drug response in cancer patients from large genomics studies. Genome Res (2017) 0.75
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol (2006) 6.95
Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization. Nat Med (2011) 3.82
Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol (2005) 3.19
Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. JAMA (2011) 3.16
Palliative sedation in end-of-life care and survival: a systematic review. J Clin Oncol (2012) 2.77
The global breast cancer burden: variations in epidemiology and survival. Clin Breast Cancer (2005) 2.69
Elf5 inhibits the epithelial-mesenchymal transition in mammary gland development and breast cancer metastasis by transcriptionally repressing Snail2. Nat Cell Biol (2012) 2.46
Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. Eur Urol (2006) 2.38
Relevance of urine telomerase in the diagnosis of bladder cancer. JAMA (2005) 2.31
Managing chronic pain: results from an open-label study using MC5-A Calmare® device. Support Care Cancer (2011) 2.29
Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials. J Clin Oncol (2011) 2.10
Modulation of mismatch repair and genomic stability by miR-155. Proc Natl Acad Sci U S A (2010) 2.05
MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2). Proc Natl Acad Sci U S A (2010) 1.99
Concern WWOX gene restoration prevents lung cancer growth in vitro and in vivo. Proc Natl Acad Sci U S A (2005) 1.84
miR-126 and miR-126* repress recruitment of mesenchymal stem cells and inflammatory monocytes to inhibit breast cancer metastasis. Nat Cell Biol (2013) 1.79
Tumor-induced osteoclast miRNA changes as regulators and biomarkers of osteolytic bone metastasis. Cancer Cell (2013) 1.62
Gastric cancer mortality in the spouses of patients who died from gastric cancer. Int J Epidemiol (2002) 1.41
Salvage treatment of relapsed or refractory germ-cell tumours. Lancet Oncol (2013) 1.39
Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study. Oncologist (2013) 1.35
Pathogenesis of osteoblastic bone metastases from prostate cancer. Cancer (2010) 1.33
p16INK4A and CDH13 hypermethylation in tumor and serum of non-small cell lung cancer patients. J Cell Physiol (2006) 1.32
Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer. Breast Cancer Res Treat (2006) 1.29
Detection and recovery of circulating colon cancer cells using a dielectrophoresis-based device: KRAS mutation status in pure CTCs. Cancer Lett (2013) 1.24
Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines. J Cell Physiol (2009) 1.19
Peripheral blood miR-328 expression as a potential biomarker for the early diagnosis of NSCLC. Int J Mol Sci (2013) 1.15
Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer. J Clin Oncol (2006) 1.14
Mutation analysis of p53, K-ras, and BRAF genes in colorectal cancer progression. J Cell Physiol (2005) 1.13
c-kit and SCF expression in normal and tumor breast tissue. Breast Cancer Res Treat (2004) 1.11
Safety and Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh A versus B Cirrhosis. Gastrointest Cancer Res (2011) 1.10
Free DNA and carcinoembryonic antigen serum levels: an important combination for diagnosis of colorectal cancer. Clin Cancer Res (2006) 1.08
Impact of palliative care unit admission on symptom control evaluated by the edmonton symptom assessment system. J Pain Symptom Manage (2005) 1.07
Addition of 5-fluorouracil to doxorubicin-paclitaxel sequence increases caspase-dependent apoptosis in breast cancer cell lines. Breast Cancer Res (2005) 1.04
Staging of breast cancer: new recommended standard procedure. Breast Cancer Res Treat (2002) 1.04
Role of RANK, RANKL, OPG, and CXCR4 tissue markers in predicting bone metastases in breast cancer patients. Clin Breast Cancer (2011) 1.03
Occupational exposure to solvents and the risk of lymphomas. Epidemiology (2006) 1.02
Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factors. Heart (2013) 1.01
Metastatic bone disease in the era of bone-targeted therapy: clinical impact. Tumori (2013) 0.99
Risk of leukemia and multiple myeloma associated with exposure to benzene and other organic solvents: evidence from the Italian Multicenter Case-control study. Am J Ind Med (2008) 0.98
Ipilimumab in advanced melanoma: reports of long-lasting responses. Melanoma Res (2012) 0.97
Prospective comparison of prognostic scores in palliative care cancer populations. Oncologist (2012) 0.97
Prognosis in advanced cancer. Hematol Oncol Clin North Am (2002) 0.96
The role of CXCR4 in the prediction of bone metastases from breast cancer: a pilot study. Oncology (2011) 0.96
177 Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study. Eur J Nucl Med Mol Imaging (2014) 0.95
Bone metastases detection by circulating biomarkers: OPG and RANK-L. Int J Oncol (2011) 0.95
Fecal multiple molecular tests to detect colorectal cancer in stool. Clin Gastroenterol Hepatol (2003) 0.95
Schedule-dependent cytotoxic interaction between epidoxorubicin and gemcitabine in human bladder cancer cells in vitro. Clin Cancer Res (2004) 0.95
A new emergency in oncology: Bone metastases in breast cancer patients (Review). Oncol Lett (2013) 0.95
Prognostic relevance of mitotic activity in patients with node-negative breast cancer. Mod Pathol (2003) 0.94
Molecular characterization of cytotoxic and resistance mechanisms induced by NCX 4040, a novel NO-NSAID, in pancreatic cancer cell lines. Apoptosis (2006) 0.94
Hormonal receptor, human epidermal growth factor receptor-2, and Ki67 discordance between primary breast cancer and paired metastases: clinical impact. Oncology (2012) 0.94
Mitotic catastrophe and apoptosis induced by docetaxel in hormone-refractory prostate cancer cells. J Cell Physiol (2008) 0.94
DNA Methylation profiles as predictors of recurrence in non muscle invasive bladder cancer: an MS-MLPA approach. J Exp Clin Cancer Res (2013) 0.94
A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer. Breast Cancer Res Treat (2013) 0.94
Prospective observational Italian study on palliative sedation in two hospice settings: differences in casemixes and clinical care. Support Care Cancer (2012) 0.93
Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: a single center study. J Transl Med (2012) 0.92
Multidisciplinary approach to the treatment of bone metastases: Osteo-Oncology Center, a new organizational model. Tumori (2009) 0.92
A validation study of the WHO analgesic ladder: a two-step vs three-step strategy. Support Care Cancer (2005) 0.91
(18)F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide. Eur J Nucl Med Mol Imaging (2015) 0.90
Basic fibroblast growth factor and vascular endothelial growth factor serum levels in breast cancer patients and healthy women: useful as diagnostic tools? Breast Cancer Res (2003) 0.90
Capecitabine versus bolus fluorouracil plus leucovorin (folinic acid) as adjuvant chemotherapy for patients with Dukes' C colon cancer : economic evaluation in an Italian NHS setting. Clin Drug Investig (2008) 0.90
Vascular endothelial growth factor and prognosis in patients with node-negative breast cancer. Int J Cancer (2002) 0.90
Adjuvant, adoptive immunotherapy with tumor infiltrating lymphocytes plus interleukin-2 after radical hepatic resection for colorectal liver metastases: 5-year analysis. J Surg Oncol (2004) 0.89
Study of molecular mechanisms of pro-apoptotic activity of NCX 4040, a novel nitric oxide-releasing aspirin, in colon cancer cell lines. J Transl Med (2007) 0.89
Multiple marker detection in peripheral blood for NSCLC diagnosis. PLoS One (2013) 0.89
Bolus fluorouracil and leucovorin with oxaliplatin as first-line treatment in metastatic colorectal cancer. J Clin Oncol (2002) 0.88
Urine cell-free DNA integrity as a marker for early bladder cancer diagnosis: preliminary data. Urol Oncol (2012) 0.88
HER-2 expression and cell proliferation: prognostic markers in patients with node-negative breast cancer. J Clin Oncol (2003) 0.88
Personal use of hair dyes and hematolymphopoietic malignancies. Arch Environ Occup Health (2007) 0.88
Short interfering RNA directed against the SLUG gene increases cell death induction in human melanoma cell lines exposed to cisplatin and fotemustine. Cell Oncol (2007) 0.87
Urine cell-free DNA integrity as a marker for early prostate cancer diagnosis: a pilot study. Biomed Res Int (2013) 0.87
Clinical implications of microRNAs in lung cancer. Semin Oncol (2011) 0.87
Chromogranin A is a potential prognostic marker in prostate cancer patients treated with enzalutamide. Prostate (2014) 0.87
Promoter methylation of tumor suppressor genes in pre-neoplastic lesions; potential marker of disease recurrence. J Exp Clin Cancer Res (2014) 0.87
Survival prediction for terminally ill cancer patients: revision of the palliative prognostic score with incorporation of delirium. Oncologist (2011) 0.86
Osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates: a retrospective study. Oncologist (2008) 0.86
Urine telomerase: an important marker in the diagnosis of bladder cancer. Neoplasia (2004) 0.85
Cisplatin in combination with zoledronic acid: a synergistic effect in triple-negative breast cancer cell lines. Int J Oncol (2013) 0.85
Hemangioblastoma of the gastrointestinal tract: a first case. Int J Surg Pathol (2013) 0.85
Accreditation for excellence of cancer research institutes: recommendations from the Italian Network of Comprehensive Cancer Centers. Tumori (2014) 0.85
Prognostic relevance of histological grade and its components in node-negative breast cancer patients. Mod Pathol (2004) 0.85
Erratum to: (18)F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide. Eur J Nucl Med Mol Imaging (2015) 0.84
Cancer mortality in a cohort of male agricultural workers from northern Italy. J Occup Environ Med (2004) 0.84
An exploratory study of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive metastatic breast cancer. Breast (2012) 0.84
Efficacy of a nitric oxide-releasing nonsteroidal anti-inflammatory drug and cytotoxic drugs in human colon cancer cell lines in vitro and xenografts. Mol Cancer Ther (2006) 0.84
Role of conventional chemosensitivity test and tissue biomarker expression in predicting response to treatment of peritoneal carcinomatosis from colon cancer. Clin Colorectal Cancer (2013) 0.84
Chromogranin A predicts outcome in prostate cancer patients treated with abiraterone. Endocr Relat Cancer (2014) 0.84
Perspectives on mTOR inhibitors for castration-refractory prostate cancer. Curr Cancer Drug Targets (2012) 0.84
Docetaxel-ST1481 sequence exerts a potent cytotoxic activity on hormone-resistant prostate cancer cells by reducing drug resistance-related gene expression. Prostate (2010) 0.84
Peritoneal carcinomatosis from ovarian cancer: chemosensitivity test and tissue markers as predictors of response to chemotherapy. J Transl Med (2011) 0.84
Urine telomerase activity for the detection of bladder cancer in females. J Urol (2007) 0.84
Zoledronic acid increases docetaxel cytotoxicity through pMEK and Mcl-1 inhibition in a hormone-sensitive prostate carcinoma cell line. J Transl Med (2008) 0.84
In vitro schedule-dependent interaction between docetaxel and gemcitabine in human gastric cancer cell lines. Clin Cancer Res (2003) 0.83
p27/kip1 expression in normal epithelium, benign and neoplastic breast lesions. J Pathol (2002) 0.83